Status:

COMPLETED

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Collaborating Sponsors:

Quintiles, Inc.

Conditions:

Advanced Parkinson's Disease

Eligibility:

All Genders

30+ years

Phase:

PHASE3

Brief Summary

The primary objective of this study was to demonstrate the superiority of levodopa - carbidopa intestinal gel over treatment with optimized oral levodopa/carbidopa during 12 weeks.

Detailed Description

Study S187.3.001 (NCT00357994) and Study S187.3.002 (NCT00660387) were 2 identically designed, Phase 3, 12-week, randomized, double-blind, double-dummy, parallel-group, multicenter studies recruiting ...

Eligibility Criteria

Inclusion

  • Idiopathic Parkinson's disease (PD) according to United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria
  • Levodopa-responsive participants who demonstrate some identifiable 'on response,' established by Investigator observation
  • Demonstrate severe motor fluctuations in spite of individually optimized treatment and where therapy options are indicated

Exclusion

  • Diagnosis is unclear or a suspicion of other parkinsonian syndromes exists such as secondary parkinsonism
  • Undergone surgery for the treatment of PD
  • Contraindications to levodopa
  • Subjects with any neurological deficit that may interfere with the study assessments

Key Trial Info

Start Date :

January 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2011

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT00357994

Start Date

January 1 2009

End Date

October 1 2011

Last Update

January 16 2015

Active Locations (15)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (15 locations)

1

Site Reference ID/Investigator# 45719

Los Angeles, California, United States, 90033

2

Site Reference ID/Investigator# 45718

Englewood, Colorado, United States, 80113

3

Site Reference ID/Investigator# 45722

Washington D.C., District of Columbia, United States, 20007

4

Site Reference ID/Investigator# 45721

Bradenton, Florida, United States, 34205